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Aryl ureas represent a new class of anti-trypanosomal agents
Xiaohui Du 1, Elizabeth Hansell 4, Juan C Engel 4, Conor R Caffrey 4,
Fred E Cohen 1;2;3 and James H McKerrow 3;4
Background: The trypanosomal diseases including Chagas' disease, African
sleeping sickness and Nagana have a substantial impact on human and animal
health worldwide. Classes of effective therapeutics are needed owing to the
emergence of drug resistance as well as the toxicity of existing agents. The
cysteine proteases of two trypanosomes, Trypanosoma cruzi (cruzain) and
Trypanosoma brucei (rhodesain), have been targeted for a structure-based drug
design program as mechanistic inhibitors that target these enzymes are effective
in cell-based and animal models of trypanosomal infection.
Results: We have used computational methods to identify new lead scaffolds for
non-covalent inhibitors of cruzain and rhodesain, have demonstrated the ef¢cacy
of these compounds in cell-based and animal assays, and have synthesized
analogs to explore structure activity relationships. Nine compounds with varied
scaffolds identi¢ed by DOCK4.0.1 were found to be active at concentrations
below 10 WM against cruzain and rhodesain in enzymatic studies. All hits were
calculated to have substantial hydrophobic interactions with cruzain. Two of the
scaffolds, the urea scaffold and the aroyl thiourea scaffold, exhibited activity
against T. cruzi in vivo and both enzymes in vitro. They also have predicted
pharmacokinetic properties that meet Lipinski's `rule of 5'. These scaffolds are
synthetically tractable and lend themselves to combinatorial chemistry efforts.
One of the compounds, 5P(1-methyl-3-tri£uoromethylpyrazol-5-yl)-thiophene
3P-tri£uoromethylphenyl urea (D16) showed a 3.1 WM IC50 against cruzain and a
3 WM IC50 against rhodesain. Infected cells treated with D16 survived 22 days in
culture compared with 6 days for their untreated counterparts. The mechanism of
the inhibitors of these two scaffolds is con¢rmed to be competitive and reversible.
Conclusions: The urea scaffold and the thiourea scaffold are promising leads for
the development of new effective chemotherapy for trypanosomal diseases.
Libraries of compounds of both scaffolds need to be synthesized and screened
against a series of homologous parasitic cysteine proteases to optimize the
potency of the initial leads.
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Introduction
Trypanosomal parasites are the cause of global health prob-
lems [1]. Chagas’ disease is the leading cause of heart
disease in Latin America [2]. Over 16 million people are
infected, with up to 80% prevalence in endemic areas, and
over 90 million are at risk [3]. It is caused by Trypanosoma
cruzi, a protozoan parasite that is transmitted to humans
from the bite of a blood-sucking insect. The trypomasti-
gote form of the insect enters the host bloodstream, ulti-
mately invades a cardiac muscle cell and then transforms
into the intracellular amastigote form. Amastigotes replicate
within cells, transform back to trypomastigotes and rupture
the cell, releasing the infectious form back into the blood-
stream and other cells, amplifying the infection [4^6]. Cur-
rently, there is no satisfactory treatment for this parasitic
infection. Because of signi¢cant toxicity, chemotherapy
with nifurtimox or benznidazole must be carried out under
close medical supervision [7]. In addition to dermatotoxic-
ity and digestive disorders, benznidazole induces chromo-
somal damage in chagasic children [8].
The major cysteine protease of T. cruzi, cruzain, is pivotal
for the development and survival of the parasite within the
host cells. Tissue culture studies of T. cruzi viability in the
presence of mechanism-based inhibitors suggest that cru-
zain is necessary for the parasite to progress through its life
cycle. Treatment of infected mice with covalent inhibitors
of cruzain has resulted in parasitological cure of the mice
[9]. Taken together, these results argue for the pharmaco-
logic utility of inhibitors of cruzain.
In central Africa, Trypanosoma brucei gambiense and T. b.
rhodesiense are the causative agent of sleeping sickness in
humans, and T. b. brucei, Trypanosoma congolense and Trypa-
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nosoma vivax are responsible for ‘Nagana’ in cattle. African
trypanosomes live extracellularly in blood and tissue £uids
of their mammalian host and are transmitted by the bite of
tsetse £ies. This complex of diseases is characterized by
waves of parasitemia in the blood with eventual in¢ltration
of the brain and central nervous system. Without treat-
ment, the infection is fatal. Over 50 million people in 36
countries are at risk of acquiring the infection and 25 000^
50 000 new cases are reported from 200 foci annually
[10,11]. Chemotherapy of African sleeping sickness is pre-
carious [12]. Only four drugs are available and three of
these were developed over 50 years ago. Treatment with
these drugs can fail and is associated with serious toxicity.
Rhodesain is the major cysteine protease of T. b. rhodesiense
(Caffrey et al., manuscript in preparation) and shares 70.0%
similarity in primary structure with cruzain. Targeting rho-
desain, and its ortholog brucipain from T. b. brucei, with
peptidyl diazomethane and phenyl vinyl sulfone inhibitors
kills trypanosomes in culture and cures mice infected with
the parasite [13,14]. Thus, rhodesain is a promising target
for the development of new trypanosomicidal drugs.
Non-covalent protease inhibitors have demonstrated suc-
cess in treatment of diseases including angiotensin-con-
verting enzyme inhibitors for hypertension and HIV pro-
tease inhibitors for AIDS [15,16]. Encouraged by these
results, we are pursuing non-covalent inhibitors of cruzain
and rhodesain for treatment of trypanosomal diseases. Our
goal is to identify compounds that are easy to synthesize
from relatively inexpensive starting materials so that the
eventual therapeutics are economically accessible to the
people who live in the areas where these diseases are
endemic.
Combinatorial chemistry and structure-based drug design
strategies are both based on the hypothesis that increas-
ingly potent agents can be found when large families of
molecules are screened. To maximize screening efforts tar-
geting diseases endemic to developing regions of the
world, we are considering families of non-covalent small
molecule inhibitors and related cysteine protease targets
in parallel. Explicitly, members of a chemical series that
are active against one parasitic protease are tested against a
series of other homologous cysteine proteases. This con-
cept proved useful in our previous work developing a ser-
ies of acyl hydrazide and chalcone-based non-covalent in-
hibitors for cruzain and rhodesain. This series was
originally developed to block falcipain, a cysteine protease
from Plasmodium falciparum [17], that is 30% identical to
cruzain. The acyl hydrazides were further optimized for
cruzain. However, the optimization of the bisaryl acylhy-
drazides failed to produce inhibitors that were more potent
than 300 nM [18,19] for cruzain and 420 nM for rhodesain
[20]. To develop more potent inhibitors for cruzain and
rhodesain and identify potential new inhibitor scaffolds,
we initiated a computational screen of ACD (Available
Chemicals Directory) database targeted against recently
solved crystal structures of cruzain [21,22]. New lead struc-
tures have been identi¢ed, that will allow us to pursue
more potent inhibitors for cruzain and rhodesain owing to
the high degree of homology between the two enzymes.
Results and discussion
Altogether 21 compounds were selected for testing against
cruzain and rhodesain following a computational screen of
the ACD97 database by DOCK4.0.1. Nine out of these 21
molecules showed IC50 values of less than 10 WM against
Figure 1. Structures of compounds having
IC50 values below 10 WM for cruzain and
rhodesain from a computational screening
of the ACD database by DOCK4.0.1.
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cruzain (Figure 1). The same nine compounds showed
IC50 values of less than 10 WM against rhodesain. Two
other compounds (D1 and D20) have IC50 values below
10 WM for rhodesain but were one order of magnitude less
active against cruzain. Altogether, 11 molecules have IC50
values below 10 WM against rhodesain. This demonstrates
a concrete advantage of our strategy for increasing the
number of effective inhibitors by testing against a set of
related targets. We have found on more than one occasion
that a given analog selected for its ef¢cacy against one
target protease is found to be more active against a related
cysteine protease. Two of the nine compounds that were
active against both proteases below 10 WM (D13 and D21)
were tested in a cell culture assay of T. cruzi infection of
mammalian cells. No toxicity against the mammalian cells
was observed. For both compounds, inhibition of parasite
replication was observed. Untreated mammalian cells in-
fected with parasites died at 6 days from parasitolysis of
cells. Cells treated with D13 or D21 survived 10 days.
The nine compounds in Figure 1 provide a wide variety of
new scaffolds for potential antiparasitic drugs, including
ureas, thioureas, amides, sulfonamides, triazoles and semi-
carbozides. In medicinal chemistry, urea bonds have been
used as critical structural elements in enzyme inhibitors
[16]. Thioureas have been found in many biological inter-
esting molecules [23^25] such as herbicides, insecticides
and plant growth regulators. Sulfonamides can be found
in numerous molecules that possess biological activity, in-
cluding many antibiotics [26,27]. Triazoles have been
found in drugs such as antifungal agent £uconazole and
in aromatase inhibitors for estrogen-dependent diseases
such as breast cancer [28,29]. A common feature of all
these structures is that they have a barbell-like structure
with two aromatic groups joined by a linker. The molecular
variety apparent in Figure 1 suggests that cruzain and rho-
desain accept a wide variety of inhibitors that contain two
aryl groups connected with an appropriate linking scaffold.
The DOCK-generated enzyme^inhibitor complexes were
re-examined to identify any common factors that could
explain their activity. All nine compounds that were active
at concentrations below 10 WM against cruzain appeared on
the energy score list. Two of them also appeared on the
contact score list. This indicates that unlike previous work
with the malarial enzyme falcipain, electrostatic issues
could not be neglected with cruzain. An examination of
the molecular surface of cruzain calculated using the
GRASP program (Figure 2) shows that while the S2 pocket
is large and prefers hydrophobic residues, it has a certain
degree of electronegativity. The S1 and S3 pockets are also
electronegative. The S1P pocket is neutral. (For notational
convenience, the amino acid residues on the acyl side of
the scissile bond are denoted P1, P2TPn and those on the
leaving group side are labeled P1P, P2PTPnP. The corre-
sponding binding sites on the enzyme are S1, S2TSn and
S1P, S2PTSnP.)
All the hits are calculated to make substantial hydrophobic
interactions with cruzain. Table 1 shows a list of cruzain
residues that each hit is thought to have hydrophobic in-
teractions with as calculated by LIGPLOT [30]. These
Figure 2. The molecular surface of cruzain
with Z-YA-FMK bound calculated by
GRASP. Red color indicates that the
surface is electronegative and purple color
indicates that the surface is electropositive.
The subsites are labeled yellow in the
¢gure.
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residues are color-coded according to the subsite pocket
that they are expected to occupy (see Figure 2 for the
pockets location). Six of the nine hits have calculated hy-
drophobic interactions with Asp158. As Asp158 has a car-
boxylate group, we are exploring the introduction of an
additional amino group on the ligand to increase the like-
lihood of forming hydrogen bonding interactions with
Asp158. Two of the six hits (D12 and D18) are calculated
to have additional interactions with two other S1P pocket
residues: Trp177 and His159. Many of these compounds
are calculated to interact with S2 pocket residues such as
Leu67, Met68, Ala133, Leu157 and Glu205.
Seven of the hits (D10, D12, D13, D17, D18, D21, D22)
exploited the S2 and S1P pockets by orienting one aromatic
end into each of these subsites in the putative docked
geometry. None of the other tested compounds including
the other two hits exploited the S1P pocket in their calcu-
lated binding mode. A representative ¢gure of the putative
binding mode between D13 and cruzain is shown in Fig-
ure 3.
Lipinski has described desired ranges for certain properties
thought to be important for pharmacokinetics and drug
development. They are CLogP 6 5, number of hydrogen
bond donors 95, number of hydrogen bond acceptors 910
and molecular weight 6 500 [31]. A compound that ful¢lls
at least three out of the four criteria is said to adhere to
Lipinski’s ‘rule of 5’. His rule was used as a ¢lter in help-
ing us to choose the reasonable scaffolds as potential lead
scaffolds. Table 2 lists the values of these properties for the
new scaffolds and suggests that these compounds are rea-
sonable starting points for a drug discovery effort. From a
synthetic point of view, most of these compounds are easy
to derivatize (e.g. D6, D10, D16, D17, D18 and D21).
As the active scaffolds are synthetically tractable structures
with the ability to inhibit the enzymes and block parasite
replication, a mimetic search was conducted to look for
chemically related molecules and test their general activ-
ities. GenX [32,33] is a program used to match compounds
that have the same substructure or pharmacophore based
on three dimensional similarity. It employs a sub-graph
isomorphism algorithm. Here we employed this program
for a computational miniscreen of the analogs. The analogs
in ACD possessing atoms within 2 Aî root mean square
(rms) of the desired core scaffolds were identi¢ed and ex-
amined visually to yield an additional 38 compounds for
investigation as cruzain/rhodesain inhibitors. These include
sixteen thioureas (D6), three aroyl ureas (D13), nine ureas
(D16), three imine sulfonamides (D10), one benzamide
(D17) and six sulfonamides (D18). There are very few
analogs of D12, D21 and D22 in the ACD.
Among these 38 compounds, ¢ve thioureas, three aroyl
Table 1
The calculated hydrophobic interactions of the cruzain^inhibi-
tor complexes by DOCK.
2Residues are color-coded according to the subsite pockets they
are located. S3 pocket residues: purple; S2 pocket residues: red;
S1 pocket residues: green; S1P pocket residues: blue. The black
residues are not easily associated with one of the pockets.
Figure 3. Stereoview of the calculated
orientation of compound D13 in the active
site of cruzain by DOCK. The color coding
of the cruzain residues is consistent with
that of Table 1. The residues are color-
coded according to the subsite pocket they
belong. S3 pocket residues: purple; S2
pocket residues: red; S1 pocket residues:
green; S1P pocket residues: blue. The
yellow residues labeled black are not
easily associated with one of the pockets.
D13 is color-coded by atom types, C: gray;
N: blue; O: red; F, Cl: purple.
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ureas, ¢ve ureas, two sulfonamides and one benzamide
were observed to have IC50 values less than 10 WM against
cruzain (see Figure 4, Tables 3 and 4 for structures). These
compounds are also active against rhodesain at concentra-
tions below 10 WM. None of the three imine sulfonamides
tested has IC50 values below 10 WM. These results indi-
cated that at least ¢ve of the scaffolds: thiourea, aroyl urea,
urea, sulfonamide and benzamide, have some degree of
generality and are possible new leads for cruzain inhibitors.
These scaffolds were further compared with the informa-
tion from database screening and assay testing.
It is interesting to note that D61 (Figure 4) differs from
D17 by having a non-aryl central ring and a benzyl-sub-
stituted amine instead of an aryl-substituted amine without
loss of activity. This indicates that the benzamide scaffold
allows some £exibility. However, this change raises the
CLogP, rendering it less attractive. D17 remains as a po-
tential lead but more information is needed about the gen-
eral activity of this series before a meaningful synthetic
strategy can be developed.
The high molecular weight and CLogP values associated
with the sulfonamides (D56, D58 in Figure 4) and the
related compounds render this scaffold less desirable.
The aroyl thiourea and urea scaffolds are common to the
largest number of active compounds identi¢ed computa-
tionally and documented experimentally for cruzain and
rhodesain. Five compounds containing each scaffold were
tested to detemine more accurate IC50 values against cru-
zain and rhodesain (Tables 3 and 4). The compounds con-
taining the aroyl thiourea scaffold generally meet the re-
quirements of Lipinski’s rule with low molecular weight
and appropriate CLogP. The analogs can be synthesized
easily in a one step reaction through addition of an aryl
amine to an aroyl isothiocyanate. When comparable sub-
stituents are considered, the compounds containing the
Table 2
The pharmacokinetic properties of the nine active compounds identi¢ed by DOCK according to Lipinski's rules.
Compound Molecular weight CLogP H-bond donors H-bond acceptors `Rule of 5' criteria met
D6 382 4.14 2 7 all
D10 470 5.62 2 5 3
D12 454 3.94 1 6 all
D13 437 6.61 2 5 3
D16 434 5.75 2 5 3
D17 480 3.84 3 5 all
D18 524 4.85 2 6 3
D21 509 6.44 3 3 2
D22 461 3.73 2 8 all
Figure 4. Structures of compounds having
activity below 10 WM possessing
benzamide, sulfonamide, and aroyl urea
scaffolds at a second stage miniscreen by
GenX. The molecular weights and
calculated CLogP values of each
compound are shown in the ¢gure.
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urea scaffold have lower molecular weights than those with
the aroyl thiourea scaffold, yet they share similar hydrogen
bond donating and accepting capabilities. In addition, the
urea moiety is more stable than a peptide bond. As a re-
sult, much attention has been paid to the syntheses and
applications of substituted ureas in recent years. They are
essential components of several drug candidates including
potent HIV reverse transcriptase inhibitors [34], CCK-B
receptor antagonists [35] and endothelin antagonists [36].
The synthesis of this type of scaffold is straightforward
either by addition of an amine to an isocyanate or an amine
to an activated carbamate [34^36]. The CLogP of the urea
scaffold is 0.3 units higher than the aroyl thiourea scaffold,
but it can be lowered conveniently by the addition of polar
functional groups or nitrogen-containing groups such as
pyridine or morpholine where the formation of HCl salt
will increase aqueous solubility.
Encouraged by these results, some of the compounds from
the aroyl thiourea scaffold and the urea scaffold were char-
acterized in the cell culture assay of T. cruzi infection of
mammalian cells. (At the time of cell culture assay, we
were running out of D28. Due to the dif¢culty of setting
up the cell culture assay and the long time needed to
purchase additional D28, no further testing was performed
on D28.) The results are shown in Table 5. Compounds
containing the urea scaffold were ef¢cacious in the cell
culture screen. Infected mammalian cells treated with
D16 survived 22 days and cells treated with D46 and
D51 survived 14 and 12 days, respectively. By comparison,
the compounds with the best in vivo activity from the acyl
hydrazide series resulted in cells surviving 17 days. Typi-
cally, cells only survive 6 days in the absence of effective
treatment.
In the aroyl thiourea scaffold, the infected cells treated
with D34 survived 8 days. However, the activity of the
other thioureas was disappointing. At this point, we initi-
ated structure^activity studies. One representative com-
pound, D217, was synthesized (Figure 5). It contained a
six-membered aryl ring connected with a ¢ve-membered
heteroaromatic ring at one side of the thiourea. This fea-
ture is present in some of the active compounds possessing
the urea scaffold, such as D16, D46, D47, D49 and D51.
From our modeling work, we believe that the six^¢ve
combination might interact with the S2 pocket better
than a single six-membered ring. D217 also has a benzyl-
substituted aryl ring on the other end of the molecule
Table 3
Structures, physical properties and detailed IC50 values of the
active compounds possessing the thiourea scaffold.
Table 4
Structures, physical properties and detailed IC50 values of the
active compounds possessing the urea scaffold.
Table 5
Results of cell culture assay of some of the active com-
pounds possessing aroyl thiourea and urea scaffolds.
Compound Results (days) Compound Results (days)
Control 6 D16 22
D23 crystals D45 toxic
D34 8 D46 14
D38 6 D49 toxic
D217 18 D51 12
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which might result in better interaction in S1P pocket.
Before generating a library of compounds possessing fea-
tures similar to D217 for a detailed SAR study, it was
tested to obtain some preliminary structure^activity infor-
mation. D217 was found to have an IC50 of 3 WM against
cruzain and 3.8 WM against rhodesain. The infected cells
treated with D217 survived 18 days, more than twice as
long as the parent compound.
A representative set of inhibitors (D51, D16, D23, D34,
two inhibitors each in the urea and the aroyl thiourea scaf-
folds) were studied for their selectivity. To our delight,
they show good selectivities. They are selective for cruzain
and rhodesain over papain, and cathepsin B within the
papain family. They do not inhibit the serine proteinase,
trypsin. Table 6 shows the detailed IC50 values of the four
inhibitors with various enzymes. A study of the time-de-
pendent inhibition of the enzyme with ¢ve compounds
including D51, D16, D23, D34 demonstrated no decrease
in enzyme activity (data not shown). This indicates that
they are reversible inhibitors. In another study of inhibi-
tion ef¢cacy as a function of increasing substrate concen-
tration, the above four inhibitors were found to show sim-
ilar behavior as leupeptin, a classical reversible competitive
inhibitor. The % of inhibition of the enzyme was reduced
with the increase of the concentration of substrate (data
not shown).
At this point, both the thiourea and urea scaffolds looked
promising based on their mechanism, speci¢city and their
in vivo and in vitro enzyme assay. Efforts are underway to
optimize these leads. Apart from their straightforward syn-
thesis, they share synthetic building blocks. The same aryl
acid and aryl amine building blocks can be used for the
generation of compound libraries for both scaffolds and
should augment the ef¢ciency of the lead optimization
process (Figure 6). Parallel synthesis can be applied for
the generation of compound libraries as a result of these
reaction conditions.
The aroyl urea scaffold is closely related to the aroyl thio-
urea scaffold (Figure 4). Thus, the aroyl thiourea synthetic
strategy can be applied to the aroyl urea scaffold. While
cell culture data for leads from this series (e.g. D13) look
promising, the hydrophobicity of these compounds as cap-
tured by the CLogP value is problematic. This will limit
analog options if we wish to remain with compounds that
share desirable pharmacokinetic features.
Signi¢cance
Our goal remains to bridge standard medicinal chemistry
strategies for compound optimization with ideas rooted in
structural studies of the enzyme inhibitor interaction. Par-
ticular attention will be paid to adding groups that facilitate
interactions with accessory subsite speci¢city pockets on
cruzain. Based on our experiences with these new lead
scaffolds and with the acyl hydrazides series, one or two
pocket interactions with cruzain can result in inhibitors
with activities at micromolar and even high nanomolar con-
centrations. We anticipate that building interactions with
accessory subsites will enhance the potency of the inhib-
itors substantially. As speci¢ed in Table 1, these inhibitors
are expected to interact with the S2 and S1P pockets. Addi-
tional fragments can be added to the inhibitors so that they
can interact with the S3 pocket. As the S2 and S3 pockets
of cruzain are electronegative, substituents such as amino
Figure 5. Synthesis of one of the
compounds possessing the aroyl thiourea
scaffold, D217.
Table 6
Selectivity of urea and aroyl thiourea inhibitors.
Inhibitor IC50 (WM)
Cruzain Papain Cathepsin B Trypsin
D51 Urea 0.8 ( þ 0.01) s 50 10.8 ( þ 0.5) s 50
D34 Thiourea 2.1 ( þ 0.05) s 50 11 ( þ 0.2) s 50
D23 Thiourea 1.5 ( þ 0.01) s 50 10.7 ( þ 0.2) s 50
D16 Urea 2.0 ( þ 0.01) s 50 11 ( þ 0.01) s 50
Leupeptin 60.1 0.18 ( þ 0.02) 0.25 ( þ 0.05) 0.11 ( þ 0.01)
The assays in this table were done in a different time from those of Tables 3 and 4, as a result, the IC50 values are slightly different
among the same inhibitors.
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groups in these pockets might increase the potency of the
inhibitors (Figure 2).
When compared to the acyl hydrazide scaffold, the aroyl
thiourea, the urea and the aroyl urea scaffolds all have
better hydrogen bonding capabilities. Though all the scaf-
folds have aryl groups at both ends, the angle and distance
between the two ends vary from one linker to the other.
The urea scaffold is more stable than the acyl hydrazide
scaffold and has a lower molecular weight. What is more
encouraging is that a compound containing the urea scaf-
fold has already demonstrated better activity in a cell cul-
ture model of trypanosomal infection than the compound
having the best activity in the acyl hydrazide series.
Materials and methods
Computational screening
Several crystal structures of cruzain bound to covalent inhibitors are
available including cruzain bound with benzoyl tyrosine alanine £uoro-
methyl ketone (Z-YA-FMK), cruzain bound with benzoyl arginine alanine
£uoromethyl ketone (Z-RA-FMK) and cruzain bound with WRR256 [37].
These were compared to identify any signi¢cant differences. The rms
deviation between cruzain bound to Z-YA-FMK and cruzain bound to Z-
RA-FMK is 0.42 Aî and for cruzain bound to Z-YA-FMK and cruzain
bound to WRR256 is 0.31 Aî . These differences are compatible with
the structural distinctions between identical proteins studied in distinct
crystal forms. For convenience, the crystal structure of cruzain bound to
Z-YA-FMK was used in our study. The movement of the Cys25 thiol
before and after the covalent linkage was also examined [38]. As the
change is relatively small (1.5 Aî ), no efforts were made to remodel the
cruzain structure. Histidines are considered positively charged (hydro-
gen on both nitrogens). The united atom Kollman charges were applied
to each residue in cruzain. These values were loaded from the BIO-
POLYMER menu in SYBYL program.
DOCK4.0.1 is an automated method to screen small-molecule data-
bases for ligands that could bind to a target protein [39]. The algorithm
¢rst generates the molecular surface of the protein with the dms function
within the UCSF MIDASPLUS program [40], which is a feature derived
from the original Connoly's surface program [41,42]. The surface is used
to generate a negative image of the active site of the protein with sets of
overlapping spheres. A grid was constructed that enclosed the entire
active site. The grid was used by DOCK to evaluate the steric boundary
of the protein and electrostatic and van der Waals interactions between
the ligand and the protein. The ligand is then ¢tted to the spheres of the
negative image of the protein and the interaction energy is calculated.
The quality of ¢t of a ligand to the active site is decided either by shape
complementarity (contact score) or by molecular mechanics force-¢eld
energy (energy score) using the AMBER potential [43]. In our case, the
residues within 7 Aî of Z-YA-FMK were selected for constructing the
molecular surface. Forty-one spheres were selected to represent the
active site of cruzain. A grid with an additional 2 Aî margin for the box
enclosing the spheres was constructed.
There are 175 413 small molecules in the ACD97 database (Molecular
Design Limited, San Leandro, CA, USA), separated into 21 sections.
The separation is for calculation convenience so that each section did
not have more than 10 000 compounds. The molecules that have heavy
atom range between 10 and 40 within the 175 413 compounds were
screened. The structures of the molecules in the database were calcu-
lated by CONCORD, a heuristic algorithm developed by R. Pearlman at
the University of Texas. Orientations of the ligands were sampled with
5000 as a limit during the DOCK run. Standard rigid body minization in
the DOCK program was applied. We did not calculate multiple confor-
mations for the ligands. The search took about 4 days on a silicon
graphics server with four parallel R10 000 processors. During the
DOCK search, the top 50 molecules by energy score and the top 50
molecules by contact score in each section were saved. The resulting
2200 compounds were visually examined several times for complemen-
tarity of the van der Waals surfaces and hydrogen bond interactions
using the molecular display software MIDASPLUS. Twenty-one com-
mercially available compounds were selected for testing against cruzain
and rhodesain. When we chose these 21 compounds from the 2200 list,
the DOCK scores are not critical in making a decision here, although
compounds that ¢t well with higher score are preferred and compounds
appearing both on contact score list and energy score list are preferred.
Peptides are not considered as we are interested in non-hydrolyzable
small molecules only. Compounds need to be able to occupy the S2
pocket as this is a deep and large pocket speci¢c for each cysteine
protease. Compounds with complicated structures are less desirable
owing to synthetic considerations. If repetitive appearance of com-
pounds with common scaffolds occurred, one or two compounds that
appear to have the best ¢tting are chosen for testing. The visual inspec-
tion of the 2200 initial list was done in triplicate to achieve consistency
and to avoid viewer bias owing to fatigue.
The CLogP values were calculated for each compound using the soft-
ware CLogP 4.51 (Daylight Chemical Information Systems, Santa Fe,
NM, USA) which is an implementation of the work of Hansch [44].
Synthesis and screening of inhibitor analogs against
recombinant cruzain
Synthesis of D217: 1-phenylsulfonyl-2-pyrrole carbonyl chloride (50 mg,
0.18 mmol), was dissolved in anhydrous dichloromethane. PEG600 (5
mg, 0.0081 mmol) and ammonium thiocyanate (21 mg, 0.27 mmol) were
added to the reaction. After stirring for 1 h under nitrogen at room
temperature, 2-amino-3-benzoloxypyridine (35 mg, 0.17 mmol) was
added to the mixture and the reaction was stirred for 2 h. Inorganic salts
were ¢ltered off from the reaction and the resulting solution was con-
centrated in vacuo. Crystallization from dichloromethane/methanol
mixed solvent afforded 30 mg of D217 (33% yield). 1H NMR (400
MHz, DMSO-d6) 8.04 (m, 3H), 7.87 (s, 1H), 7.73 (t, 1H, J = 7.5 Hz),
7.61 (t, 3H, J = 7.6 Hz), 7.48 (d, 2H, J = 7.2 Hz), 7.31 (m, 4H), 7.20
(m, 1H), 6.49 (t, 1H, J = 3.2 Hz), 5.24 (s, 2H). MS(FAB) (M+H) calculated
for C24H20N4O4S2 493.6, found 493.0.
IC50, inhibitor mechanism and speci¢city determinations. All other inhib-
itors were purchased from Aldrich and Ryan Scienti¢c. Inhibitors were
screened for effectiveness against the T. cruzi cathepsin L-like protease
(cruzain) using puri¢ed recombinant protein [45]. Cruzain (2 nM) was
incubated with 500^10 000 nM inhibitor in 100 mM sodium acetate buff-
er (pH 5.50) and 5 mM dithiothreitol (buffer A), for 5 min at room temper-
ature. Buffer A containing Z-Phe-Arg-AMC (Bachem, Km = 1 WM) was
added to enzyme inhibitor to give 20 WM substrate in 200 Wl, and the
Figure 6. The synthesis of the compounds possessing the aroyl
thiourea and urea scaffolds can apply common building blocks.
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increase in £uorescence (excitation at 355 nM and emission at 460 nM)
was followed with an automated microtiter plate spectro£uorimeter (Mo-
lecular Devices, spectraMAX Gemini). Inhibitor stock solutions were
prepared at 20 mM in DMSO and serial dilutions were made in
DMSO (0.7% DMSO in assay). Controls were performed using enzyme
alone, and enzyme with DMSO. IC50 values were determined graphi-
cally using inhibitor concentrations in the linear portion of a plot of inhi-
bition versus log [I] (seven concentrations tested with at least two in the
linear range). IC50 values for other cysteine proteases were determined
similarly: rhodesain (recombinant, cysteine protease from T. b. rhode-
siense, EC 3.4.22.X, gift of Conor Caffrey) at 3 nM and 10 WM Z-Phe-
Arg-AMC (Km = 1 WM); papain (EC 3.4.22.2, Sigma) at 6 nM enzyme and
100 WM Z-Phe-Arg-AMC (Km = 50 WM); cathepsin B (bovine spleen, EC
3.4.22.1, Sigma) at 10 nM enzyme and 100 WM Z-Phe-Arg-AMC
(Km = 110 WM); and cathepsin S (recombinant human, EC 3.4.22.27,
gift of Dieter Bromme) at V10 nM enzyme and 20 WM Z-Phe-Arg-
AMC (Km = 20 WM). The IC50 determinations for the serine proteinase
trypsin (bovine pancreatic, EC 3.4.21.4, Cal Biochem) were done in 100
WM Tris pH 8 and 2 mM CaCl2 with 20 WM Z-Phe-Arg-AMC and enzyme
at 1.25 ng per 200 Wl assay. Time dependence of inhibition was deter-
mined by incubating cruzain with inhibitors, DMSO or enzyme alone at
room temperature for time points between 30 s and 2 h and the activity
determined as above. Substrate inhibitor competition with cruzain and
selected inhibitors was done with 0.5^90 WM Ac-Lys-Glu-Lys-Leu-Arg-
AMC (gift of Smith Kline Beecham) (Km = 1 WM). Leupeptin (Roche), a
classical competitive inhibitor, was used as a control. Similar experi-
ments were done using cathepsin S and 2^100 WM Z-Phe-Arg-AMC.
Enzyme (0.1Uvolume) was added to a mixture of inhibitor and substrate
(0.9Uvolume), with the % of DMSO kept constant at 1.5%. Controls of
enzyme alone and enzyme with DMSO were done. Inhibition mecha-
nism was determined by plots of % inhibition against substrate concen-
tration (K.F. Tipton, Chapter 4, `Patterns of Enzyme Inhibition', in Enzy-
mology Labfax, ed. P.C. Engel).
Tissue culture models of T. cruzi infection: growth inhibition of
T. cruzi amastigotes by cysteine protease inhibitors
J774 macrophages were cultured in RPMI 1640 medium and 5% heat-
inactivated FCS (RPMI medium). For growth inhibition assays, J774
macrophages were irradiated (3000 rad) to arrest cell growth and cul-
tured on coverglasses within six-well plates for 24 h at 37³C. After
infection with T. cruzi trypomastigotes of the Y strain for 3 h, monolayers
were washed with RPMI medium and treated with inhibitors at 7.5 WM in
RPMI medium. Inhibitor stocks were made at 7.5 mM in DMSO and all
assays included DMSO (0.01^0.02% v/v) controls. The inhibitors were
evaluated in T. cruzi-infected macrophage cultures for 24 days. Trypo-
mastigote output, indicative of the completion of the intracellular cycle,
was then assayed in treated and untreated cultures to determine growth
inhibition of intracellular T. cruzi amastigotes. In untreated cultures, par-
asites destroy mammalian cells at the end of their 6 day cycle of rep-
lication.
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